Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:TPIV

TapImmune (TPIV) Stock Price, News & Analysis

About TapImmune Stock (NASDAQ:TPIV)

Advanced Chart

Key Stats

Today's Range
$8.01
$8.40
50-Day Range
$8.34
$8.34
52-Week Range
$2.58
$13.55
Volume
100,653 shs
Average Volume
235,808 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Receive TPIV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TapImmune and its competitors with MarketBeat's FREE daily newsletter.

TPIV Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

TPIV Stock Analysis - Frequently Asked Questions

TapImmune, Inc. (NASDAQ:TPIV) released its earnings results on Thursday, August, 9th. The company reported ($0.41) earnings per share for the quarter. The business earned $0.21 million during the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that TapImmune investors own include Verastem (VSTM), Viking Therapeutics (VKTX), Coherus BioSciences (CHRS), Portola Pharmaceuticals (PTLA), Rigel Pharmaceuticals (RIGL), Fate Therapeutics (FATE) and Galectin Therapeutics (GALT).

Company Calendar

Last Earnings
8/09/2018
Today
5/13/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:TPIV
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:TPIV) was last updated on 5/13/2025 by MarketBeat.com Staff
From Our Partners